Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study ID
NCT02470585

Study type
Interventional

Study phase
Phase 3

Study status
Terminated

Trial Acronym

VELIA

Trial Summary

The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with chemotherapy alone.

More informations

Trial Starting Date

Jun 29,2015

Requirements

Gender Female
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

1140